Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Lamina Soft With Different Collagen Based Materials in Bone Regeneration

30 avril 2026 mis à jour par: Nicola Alberto Valente, DDS, MS, PhD

Use of OsteoBiol® Lamina® Soft and Different Collagen-based Graft Materials in Bone Regeneration: A Pilot Prospective Controlled Clinical Trial

This prospective controlled clinical pilot study will compare the effectiveness of two different grafting strategies for horizontal bone regeneration in healed post-extraction sites with buccal bone deficiency, using a collagenated porcine cortical bone lamina as a barrier membrane.

A total of 21 patients requiring implant-supported rehabilitation associated with bone regeneration will be enrolled, for a total of 40 implants. In the test group, bone defects will be grafted using a collagenated cortico-cancellous sticky xenograft, while in the control group a mixture of hydroxyapatite-based xenograft and autologous bone in a 1:1 ratio will be used. In both groups, a semi-rigid collagenated cortical bone lamina will be applied and stabilized to contain the graft material and maintain space for regeneration.

The primary objective of the study will be to evaluate volumetric bone changes over time using cone-beam computed tomography imaging, comparing baseline and follow-up scans. Secondary outcomes will include linear measurements of bone gain at different levels around the implant site.

The study will investigate whether collagenated xenografts alone can provide comparable clinical and radiographic outcomes to combined grafting approaches including autologous bone, while potentially reducing patient morbidity associated with bone harvesting.

Aperçu de l'étude

Description détaillée

Severe alveolar ridge resorption following tooth extraction may result in insufficient bone width and compromised anatomical conditions for implant placement, particularly in sites with buccal cortical plate deficiency. In such cases, guided bone regeneration (GBR) procedures will be required to restore adequate bone volume and allow for prosthetically driven implant rehabilitation.

A wide range of grafting materials will be used in clinical practice for bone regeneration, including autologous bone, allogeneic and xenogeneic biomaterials, as well as synthetic substitutes. Among these, xenogeneic collagenated grafts will be increasingly adopted due to their favorable biological properties, including clot stabilization, facilitation of early cellular infiltration, and promotion of angiogenesis. However, their relatively rapid remodeling rate may influence the final volumetric stability of the regenerated bone.

Barrier membranes will play a crucial role in GBR procedures by preventing soft tissue invasion and maintaining space for bone regeneration. Recently, collagenated porcine cortical bone laminae will be introduced as semi-rigid membranes combining the advantages of mechanical stability and biocompatibility. When properly stabilized, these devices will act as containment structures for graft materials, potentially improving regenerative outcomes.

The present study will be designed as a prospective controlled clinical trial to evaluate the effectiveness of two different grafting strategies for horizontal bone regeneration in healed post-extraction sites presenting buccal bone deficiency. Patients requiring implant-supported rehabilitation associated with bone augmentation procedures will be consecutively enrolled and allocated to one of two treatment groups.

In the test group, bone defects will be grafted using a collagenated cortico-cancellous sticky xenograft. In the control group, a mixture of hydroxyapatite-based xenograft and autologous bone in a 1:1 ratio will be used. In both groups, a collagenated porcine cortical bone lamina will be applied as a barrier membrane and stabilized using fixation pins to ensure space maintenance and graft containment.

All surgical procedures will be performed under local anesthesia by an experienced operator following standardized clinical protocols. After implant placement and grafting, primary wound closure will be achieved, and patients will receive appropriate postoperative care, including antibiotics and analgesics as indicated. Sutures will be removed after a healing period of approximately 10-14 days.

Radiographic evaluation will be performed using cone-beam computed tomography (CBCT) scans acquired before surgery (baseline) and at follow-up. Digital datasets will be analyzed using dedicated three-dimensional software to assess volumetric changes in the regenerated bone. Linear measurements will also be obtained at predefined reference levels around the implant site, including the implant neck, 3 mm apically, and at the implant apex.

Implant-supported prosthetic rehabilitation will be completed after a healing period of approximately six months, following confirmation of implant osseointegration.

The primary outcome of the study will be the volumetric change of regenerated bone over time. Secondary outcomes will include linear bone gain at different levels and the influence of clinical and anatomical variables such as patient age, sex, and implant site localization.

Statistical analysis will be performed at the implant level. Continuous variables will be assessed for normality and compared between groups using appropriate parametric or non-parametric tests. Multivariable regression models will be applied to evaluate the association between treatment group and outcomes while adjusting for potential confounding variables.

This study will aim to determine whether collagenated xenografts alone will provide comparable regenerative outcomes to combined approaches including autologous bone, potentially reducing surgical invasiveness and donor-site morbidity while maintaining adequate bone volume for implant-supported rehabilitation.

Type d'étude

Interventionnel

Inscription (Réel)

40

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Cagliari
      • Cagliari, Cagliari, Italie, 09125
        • Università di Cagliari

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Healed type II post-extraction sockets according to the Elian classification
  • Age between 18 and 80 years
  • Good periodontal control, defined as treated periodontitis with plaque index <25% and bleeding on probing <25%
  • ASA I or ASA II systemic status
  • Ability and willingness to provide written informed consent
  • Ability and willingness to attend scheduled follow-up visits

Exclusion Criteria:

  • Smoking more than 10 cigarettes per day
  • Active oral infections
  • Mucosal diseases, including erosive lichen planus
  • History of radiotherapy in the head and neck region
  • Systemic diseases affecting bone metabolism or contraindicating oral surgery
  • Non-compliance or inability to complete follow-up
  • Extraction sockets with intact bone walls

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Collagenated Xenograft + Cortical Lamina
Participants in this arm will undergo horizontal bone regeneration using a collagenated cortico-cancellous xenogeneic graft material. The graft will be placed in healed post-extraction sites presenting buccal bone deficiency. A collagenated porcine cortical bone lamina will be used as a semi-rigid barrier membrane and stabilized with fixation pins to contain the graft and maintain space for bone regeneration. Implant placement will be performed in conjunction with the regenerative procedure.
Participants will undergo implant placement combined with guided bone regeneration in healed post-extraction sites with buccal bone deficiency. The surgical procedure will include defect debridement, graft placement, and stabilization using a collagenated porcine cortical bone lamina as a semi-rigid barrier membrane fixed with pins. Primary closure will be achieved, and postoperative care will follow standard clinical protocols.
A collagenated cortico-cancellous xenogeneic bone graft material will be used to fill the bone defect during guided bone regeneration procedures. The material will be applied to promote early vascularization and cellular infiltration, supporting bone regeneration while undergoing physiological remodeling over time.
Comparateur actif: Hydroxyapatite Xenograft + Autologous Bone + Cortical Lamina
Participants in this arm will undergo horizontal bone regeneration using a mixture of hydroxyapatite-based xenogeneic graft material and autologous bone in a 1:1 ratio. The graft will be placed in healed post-extraction sites with buccal bone deficiency. A collagenated porcine cortical bone lamina will be used as a semi-rigid barrier membrane and stabilized with fixation pins to ensure graft containment and space maintenance. Implant placement will be performed in conjunction with the regenerative procedure.
Participants will undergo implant placement combined with guided bone regeneration in healed post-extraction sites with buccal bone deficiency. The surgical procedure will include defect debridement, graft placement, and stabilization using a collagenated porcine cortical bone lamina as a semi-rigid barrier membrane fixed with pins. Primary closure will be achieved, and postoperative care will follow standard clinical protocols.
A mixture of hydroxyapatite-based xenogeneic bone graft and autologous bone in a 1:1 ratio will be used to fill the bone defect during guided bone regeneration procedures. The autologous component will provide osteogenic and osteoinductive potential, while the xenograft will contribute to long-term volume stability.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Volumetric Bone Change
Délai: Baseline to 24-36 months after surgery
Change in regenerated bone volume will be assessed using cone-beam computed tomography scans acquired at baseline and follow-up. DICOM datasets will be superimposed and analyzed with dedicated three-dimensional software. Regenerated bone volume will be expressed in cubic millimeters.
Baseline to 24-36 months after surgery

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Linear Bone Gain at Implant Neck
Délai: Baseline to 24-36 months after surgery
Horizontal linear bone gain will be measured on cone-beam computed tomography scans at the implant neck level.
Baseline to 24-36 months after surgery
Linear Bone Gain 3 mm Apical to Implant Neck
Délai: Baseline to 24-36 months after surgery
Horizontal linear bone gain will be measured on cone-beam computed tomography scans at 3 mm apical to the implant neck.
Baseline to 24-36 months after surgery
Linear Bone Gain at Implant Apex
Délai: Baseline to 24-36 months after surgery
Horizontal linear bone gain will be measured on cone-beam computed tomography scans at the implant apex level.
Baseline to 24-36 months after surgery

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 juillet 2022

Achèvement primaire (Réel)

30 janvier 2026

Achèvement de l'étude (Réel)

30 janvier 2026

Dates d'inscription aux études

Première soumission

30 avril 2026

Première soumission répondant aux critères de contrôle qualité

30 avril 2026

Première publication (Réel)

7 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

7 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

30 avril 2026

Dernière vérification

1 avril 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data underlying the results reported in this study will be made available upon reasonable request to the corresponding author, following publication of the study results. Data sharing will be subject to institutional policies and applicable regulations to ensure patient confidentiality and data protection.

Délai de partage IPD

Data will be available beginning 6 months following publication of the primary results and will remain available for up to 5 years.

Critères d'accès au partage IPD

Access to de-identified individual participant data and supporting documents will be granted to researchers who provide a methodologically sound research proposal. Requests will be reviewed by the study investigators. Data will be shared after approval of a data access agreement and in compliance with institutional policies and applicable data protection regulations. Data will be made available upon reasonable request to the corresponding author.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner